Vepugratinib + EV + Pembrolizumab
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Transitional Cell
Conditions
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Trial Timeline
Dec 12, 2025 → May 1, 2033
NCT ID
NCT07218380About Vepugratinib + EV + Pembrolizumab
Vepugratinib + EV + Pembrolizumab is a phase 3 stage product being developed by Eli Lilly for Carcinoma, Transitional Cell. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07218380. Target conditions include Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07218380 | Phase 3 | Recruiting |
Competing Products
20 competing products in Carcinoma, Transitional Cell